Alzheimer disease is the most common form of dementia, affecting more than one-third of Americans older than 85 years. It is characterized by progressive memory loss and cognitive decline. Amyloid plaque accumulation, neurofibrillar tau tangles, and depletion of acetylcholine are among the pathologic manifestations of Alzheimer disease. Although there are no proven modalities for preventing Alzheimer disease, hypertension treatment, omega-3 fatty acid supplementation, physical activity, and cognitive engagement demonstrate modest potential. Acetylcholinesterase inhibitors are first-line medications for the treatment of Alzheimer disease, and are associated with mild improvements in cognitive function, behavior, and activities of daily living; however, the clinical relevance of these effects is unclear. The most common adverse effects of acetylcholinesterase inhibitors are nausea, vomiting, diarrhea, dizziness, confusion, and cardiac arrhythmias. Short-term use of the N-methyl-D-aspartate receptor antagonist memantine can modestly improve measures of cognition, behavior, and activities of daily living in patients with moderate to severe Alzheimer disease. Memantine can also be used in combination with acetylcholinesterase inhibitors. Memantine is generally well tolerated, but whether its benefits produce clinically meaningful improvement is controversial. Although N-methyl-D-aspartate receptor antagonists and acetylcholinesterase inhibitors can slow the progression of Alzheimer disease, no pharmacologic agents can reverse the progression. Atypical antipsychotics can improve some behavioral symptoms, but have been associated with increased mortality rates in older patients with dementia. There is conflicting evidence about the benefit of selegiline, testosterone, and ginkgo for the treatment of Alzheimer disease. There is no evidence supporting the beneficial effects of vitamin E, estrogen, or nonsteroidal anti-inflammatory drug therapy. (Am Fam Physician. 2011;83(12):1403-1412. Copyright © 2011 American Academy of Family Physicians.)
Acetylcholinesterase inhibitors are modestly effective in patients with mild to moderate Alzheimer disease, although limited by their adverse effects.

Combination therapy with an acetylcholinesterase inhibitor and memantine (Namenda) should be considered in patients with moderate to severe Alzheimer disease.

Atypical antipsychotic agents can improve some behavioral manifestations of Alzheimer disease but are associated with increased mortality in older patients.

Nonsteroidal anti-inflammatory drugs, vitamin E, testosterone, estrogen, statins, and insulin sensitizers are not recommended for the treatment of Alzheimer disease.

Physicians should consider discontinuing treatment for Alzheimer disease in patients who continue to decline despite maximal therapy.

**A** = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Medications

Acetylcholinesterase inhibitors reversibly bind and inactivate the enzyme that degrades acetylcholine, which is involved in memory. Donepezil (Aricept) is the only acetylcholinesterase inhibitor approved for use in all stages of the disease. The N-methyl-D-aspartate receptor antagonist memantine (Namenda) is approved for treating moderate to severe disease, and is thought to prevent excitatory amino acid neurotoxicity without interfering with the physiologic actions of glutamate, a neurotransmitter necessary for learning and memory. Studies of these drugs have usually assessed effectiveness using one of several scales, such as the Alzheimer’s Disease Assessment Scale for Cognition (ADAS-cog; a 70-point scale), the Alzheimer’s Disease Cooperative Study Activities of Daily Living inventory (ADCS-ADL; a 54-point scale), or the Severe Impairment Battery (SIB; a 100-point scale). In general, to be clinically significant (defined as a noticeable improvement by the patient or caregiver), an increase should be at least 10 percent of the scale length (i.e., 7 points on the ADAS-cog, 5 points on the ADCS-ADL, or 10 points on the SIB).

**ACETYLCHOLINESTERASE INHIBITORS**

Acetylcholinesterase inhibitors are first-line agents for the treatment of mild to moderate Alzheimer disease, according to existing guidelines. Most randomized controlled trials and systematic reviews have found no notable differences in effectiveness among the various acetylcholinesterase inhibitors. Despite small variations in mechanisms of action, these agents have varying adverse effect profiles (Table 2). The most common adverse effects are nausea, vomiting, and diarrhea; cardiovascular and neurologic adverse effects are comparable. The incidence of adverse effects is directly related to the dose administered. Rivastigmine (Exelon) patches may be better tolerated than oral rivastigmine. Tacrine is no longer available because of safety and tolerability concerns.

A Cochrane review concluded that in patients with Alzheimer disease, treatment with donepezil, galantamine (Razadyne), or rivastigmine for six months to one year resulted in slightly improved cognitive function by an average of –2.7 points on the ADAS-cog. Improvements in behavior and activities of daily living also have been noted in patients treated with one of these three agents; however, none of the medications have

### Table 1: Clinical Recommendations for Practice

<table>
<thead>
<tr>
<th>Clinical recommendation</th>
<th>Evidence rating</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylcholinesterase inhibitors are modestly effective in patients with mild to moderate Alzheimer disease, although limited by their adverse effects.</td>
<td>A</td>
<td>12</td>
</tr>
<tr>
<td>Combination therapy with an acetylcholinesterase inhibitor and memantine (Namenda) should be considered in patients with moderate to severe Alzheimer disease.</td>
<td>B</td>
<td>27</td>
</tr>
<tr>
<td>Atypical antipsychotic agents can improve some behavioral manifestations of Alzheimer disease but are associated with increased mortality in older patients.</td>
<td>B</td>
<td>31, 33</td>
</tr>
<tr>
<td>Nonsteroidal anti-inflammatory drugs, vitamin E, testosterone, estrogen, statins, and insulin sensitizers are not recommended for the treatment of Alzheimer disease.</td>
<td>B</td>
<td>34-43, 46-49</td>
</tr>
<tr>
<td>Physicians should consider discontinuing treatment for Alzheimer disease in patients who continue to decline despite maximal therapy.</td>
<td>C</td>
<td>16</td>
</tr>
</tbody>
</table>
**Table 1. Clinical Dementia Rating**

<table>
<thead>
<tr>
<th>Impairment</th>
<th>None (0)</th>
<th>Questionable (0.5)</th>
<th>Mild (1)</th>
<th>Moderate (2)</th>
<th>Severe (3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memory</td>
<td>No memory loss or slight inconsistent forgetfulness</td>
<td>Consistent slight forgetfulness; partial recollection of events; “benign” forgetfulness</td>
<td>Moderate memory loss; more marked for recent events; defect interferes with everyday activities</td>
<td>Severe memory loss; only highly learned material retained; new material rapidly lost</td>
<td>Severe memory loss; only fragments remain</td>
</tr>
<tr>
<td>Orientation</td>
<td>Fully oriented</td>
<td>Fully oriented except for slight difficulty with time relationships</td>
<td>Moderate difficulty with time relationships; oriented for place at examination; may have geographic disorientation elsewhere</td>
<td>Severe difficulty with time relationships; usually disoriented to time, often to place</td>
<td>Oriented to person only</td>
</tr>
<tr>
<td>Judgment and problem solving</td>
<td>Solves everyday problems and handles business and financial affairs well; judgment good in relation to past performance</td>
<td>Slight impairment in solving problems, determining similarities and differences</td>
<td>Severe difficulty in solving problems, determining similarities and differences; social judgment usually maintained</td>
<td>Unable to make judgments or solve problems</td>
<td></td>
</tr>
<tr>
<td>Community affairs</td>
<td>Independent function at usual level in job, shopping, and volunteer and social groups</td>
<td>Slight impairment in these activities</td>
<td>Unable to function independently at these activities, although may still be engaged in some; appears normal to casual inspection</td>
<td>No pretense of independent function outside of home; appears well enough to be taken to functions outside a family home</td>
<td>No pretense of independent function outside of home; appears too ill to be taken to functions outside a family home</td>
</tr>
<tr>
<td>Home and hobbies</td>
<td>Life at home, hobbies, and intellectual interests well maintained</td>
<td>Life at home, hobbies, and intellectual interests slightly impaired</td>
<td>Mild but definite impairment of function at home; more difficult chores abandoned; more complicated hobbies and interests abandoned</td>
<td>Only simple chores preserved; interests very restricted and poorly maintained</td>
<td>No significant function in home</td>
</tr>
<tr>
<td>Personal care</td>
<td>Fully capable of self-care</td>
<td>Fully capable of self-care</td>
<td>Needs prompting</td>
<td>Requires assistance in dressing, hygiene, keeping of personal effects</td>
<td>Requires much help with personal care; frequent incontinence</td>
</tr>
</tbody>
</table>

Global Clinical Dementia Rating score: 0 = normal cognitive function; 0.5 = very mild dementia; 1 = mild dementia; 2 = moderate dementia; 3 = severe dementia.

**Note:** Only one box should be marked in each category. Score only as decline from previous usual level due to cognitive loss, not impairment due to other factors. If the physician feels that the patient could be rated in either of the two adjacent boxes, the box of greater impairment should be checked. The global Clinical Dementia Rating score is derived from the scores in each of the six categories. Memory is the primary category, with all others being secondary. The overall score is equivalent to the memory portion score if at least three secondary categories are given the same score as the memory portion, or if one-half of the secondary categories are greater and one-half are less than the memory portion score. If at least three secondary categories score greater or less than the memory portion, the overall score is equal to the score of the majority of the secondary categories.

Physicians using this tool should participate in the Brief Training and Reliability Protocol, which can be completed online through Washington University’s Alzheimer’s Disease Research Center at [http://alzheimer.wustl.edu/](http://alzheimer.wustl.edu/).


A large treatment effect, and the clinical significance of these effects is questionable. Another systematic review concluded that, despite statistical significance, the improvement in patients with dementia taking acetylcholinesterase inhibitors was clinically marginal (−0.1 to −5.3 points on the ADAS-cog). Additional trials are needed to determine the benefits of long-term therapy and whether these agents are effective in patients with moderate to severe Alzheimer disease. It is reasonable to discontinue treatment if there is no improvement within...
six to eight weeks. Therapy may be restarted if symptoms worsen after the medication is tapered, because acetylcholinesterase inhibitors may be more effective for symptomatic control than previously recognized.25

### Table 2. Medications for Treating Alzheimer Disease

<table>
<thead>
<tr>
<th>Medication*</th>
<th>Common dosage</th>
<th>Pharmacologic actions</th>
<th>Adverse effects and expected incidence (overall %)22,23,†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acetylcholinesterase inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donepezil (Aricept)</td>
<td>10 mg per day</td>
<td>Centrally active, reversible, and noncompetitive acetylcholinesterase inhibitor</td>
<td>Any adverse effect (15.1 to 71.3) Discontinuation because of adverse effects (2.5 to 14.6) Any gastrointestinal adverse effect (4.5 to 23.8) Nausea (1.4 to 19) Diarrhea (0 to 15) Headache (2.4 to 14) Insomnia (0 to 14) Agitation (3 to 12.5) Dizziness (10) Vomiting (0 to 9)</td>
</tr>
<tr>
<td>Galantamine (Razadyne)</td>
<td>8 mg twice per day, or 16 mg extended-release formulation once per day</td>
<td>Reversible, competitive acetylcholinesterase inhibitor that also acts on nicotinic acetylcholine receptors</td>
<td>Any adverse effect (31.9 to 55) Discontinuation because of adverse effects (2.4 to 21.1) Any gastrointestinal adverse effect (24) Nausea (0 to 24) Vomiting (1.9 to 13) Cardiac arrhythmia (3.9 to 12.5) Diarrhea (5.8 to 12) Confusion (11.1) Headache (8 to 11) Dizziness (1 to 10)</td>
</tr>
<tr>
<td>Rivastigmine (Exelon)</td>
<td>6 mg orally twice per day or 9.5 mg per 24-hour patch</td>
<td>Reversible carbamate acetylcholinesterase inhibitor that interacts preferentially with acetylcholinesterase G1</td>
<td>Any adverse effect (20.1 to 78) Discontinuation because of adverse effects (3.1 to 40) Nausea (0.8 to 47) Any gastrointestinal adverse effect (6.3 to 39) Vomiting (0.8 to 31) Weight loss (3 to 26) Dizziness (2 to 21) Diarrhea (0 to 19) Cardiac arrhythmia (0 to 18.8) Loss of appetite (3 to 17)</td>
</tr>
<tr>
<td><strong>NMDA receptor antagonist</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Memantine (Namenda)</td>
<td>10 mg twice per day</td>
<td>Low to moderate affinity NMDA receptor antagonist that binds to NMDA receptor–operated cation channels; prevents glutamatergic overstimulation at NMDA receptor</td>
<td>Adverse effects and dropout rates not statistically different from placebo Dizziness (5 to 7) Confusion (6) Headache (6) Diarrhea (2 to 5) Vomiting (2 to 3)</td>
</tr>
</tbody>
</table>

NA = not available; NMDA = N-methyl-D-aspartate.

*—Medications do not reverse the symptoms of dementia but may slow their course.
†—Adverse effects are listed in order of expected incidence, from most to least likely.
‡—Systematic reviews have found no significant differences in effectiveness among acetylcholinesterase inhibitors.
§—Estimated retail price of one month’s treatment based on information obtained at http://www.drugstore.com (accessed March 9, 2011).

Information from references 21 through 23.

**MEMANTINE**

Memantine prevents excessive glutamatergic activity. A Cochrane review concluded that memantine at a dosage of 20 mg per day over six months slightly improved
Alzheimer Disease

<table>
<thead>
<tr>
<th>Evidence of benefit( ^{21,23} )</th>
<th>Cost of generic (brand)( ^{35} )</th>
</tr>
</thead>
<tbody>
<tr>
<td>A dosage of 5 to 10 mg per day mildly improves cognition and global function</td>
<td>$180 ($276)</td>
</tr>
<tr>
<td>No benefit seen in patients with mild cognitive impairment</td>
<td></td>
</tr>
<tr>
<td>May slow development of disease in the short term, but not after 36 months</td>
<td></td>
</tr>
<tr>
<td>Improves cognition and global function</td>
<td>$140 ($225) for 8 mg twice per day</td>
</tr>
<tr>
<td>Inconsistent evidence for change in activities of daily living</td>
<td>$120 ($226) for 16 mg extended release once per day</td>
</tr>
<tr>
<td>Short duration of studies limits interpretation of use beyond six months</td>
<td></td>
</tr>
<tr>
<td>Effect size on cognition not statistically significant</td>
<td>Capsules: NA ($257)</td>
</tr>
<tr>
<td>May have some benefit in activities of daily living up to 12 months</td>
<td>Patches: NA ($255)</td>
</tr>
<tr>
<td>A dosage of 20 mg per day has positive effect on cognition in patients with mild, moderate, or severe Alzheimer disease</td>
<td>NA ($210)</td>
</tr>
<tr>
<td>Mood, behavior, and activities of daily living improved in patients with moderate to severe Alzheimer disease</td>
<td></td>
</tr>
</tbody>
</table>

Patients with mild to moderate dementia (1 point on the ADAS-cog) but is unlikely to have clinical significance. A small reduction in agitation was seen in patients taking memantine. Seventeen patients with moderate to severe Alzheimer disease would need to be treated for six months to prevent one episode of agitation.\(^{13}\)

A meta-analysis concluded that memantine was ineffective for patients with mild Alzheimer disease, and the benefits for patients with moderate Alzheimer disease were inconsistent.\(^{26}\)

Memantine is generally well tolerated and is often used with acetylcholinesterase inhibitors. One study randomized patients taking donepezil for moderate to severe Alzheimer disease to receive 20 mg of memantine or placebo every day for 24 weeks.\(^{27}\) Patients taking memantine showed mild improvement in cognition (+0.9 points versus –2.5 points with placebo on the SIB) and activities of daily living (~2.0 points versus –3.4 points with placebo on the ADCS-ADL). Another study evaluated the effectiveness and safety of 20 mg of memantine per day for 24 weeks in patients already taking donepezil, rivastigmine, or galantamine for mild to moderate Alzheimer disease.\(^{28}\) Adding memantine was not associated with a statistically significant improvement compared with placebo. The lack of adverse effects was consistent with findings in other memantine mono-therapy studies.\(^{15,28}\)

Guidelines from the National Institute for Health and Clinical Excellence cite a study that found no improvement with memantine compared with placebo in patients who had moderate to severe Alzheimer disease.\(^{14}\) Patients taking memantine may have problems with adherence because it is typically taken twice per day. A once-daily extended-release formulation of memantine was approved by the U.S. Food and Drug Administration in June 2010.\(^{22}\)

SELEGILINE

Selegiline (Eldepryl) is a monoamine oxidase type B inhibitor with minimal anticholinergic effects. A Cochrane review analyzed 17 double-blind, randomized, placebo-controlled trials evaluating selegiline at a dosage of 10 mg per day for the treatment of Alzheimer disease. The authors concluded that cognition improved at four to six weeks in some trials; however, there were no differences after six weeks.\(^{29}\) The benefits were found primarily in two studies; other trials did not support these findings. No differences in adverse effects were noted compared with placebo. Currently, there is not enough evidence to recommend selegiline for the treatment of Alzheimer disease.
Antipsychotics

Antipsychotics are not approved by the U.S. Food and Drug Administration for the treatment of Alzheimer disease, although they are commonly used to treat behavioral symptoms. Evidence suggests that olanzapine (Zyprexa) and risperidone (Risperdal) reduce aggression, and risperidone reduces psychosis in patients with Alzheimer disease.\(^{30}\) The Clinical Antipsychotic Trials of Intervention Effectiveness protocol for Alzheimer disease assessed the effects of atypical antipsychotics on psychiatric and behavioral symptoms.\(^{31}\) It included 421 outpatients with Alzheimer disease and psychosis or agitated/aggressive behavior. Patients were randomized to receive olanzapine, quetiapine (Seroquel), risperidone, or placebo for up to 36 weeks. There were no clinically or statistically significant differences in functioning, care needs, or quality of life between patients taking antipsychotics and those taking placebo. Some clinical symptoms improved, such as anger, aggression, and paranoia. Patients taking olanzapine experienced worsening functional ability at week 12 compared with those taking placebo. A small randomized, double-blind, placebo-controlled trial failed to demonstrate effectiveness of quetiapine or rivastigmine for treatment of agitation in patients with Alzheimer disease in care facilities after 26 weeks.\(^{32}\) At six weeks, a statistically significant decline in cognition was noted in patients taking quetiapine compared with those taking placebo.

Older patients with dementia who are treated with atypical antipsychotics have a twofold higher mortality rate than those taking placebo.\(^{33}\) One study found that new use of atypical antipsychotics was associated with an increased risk of death at 30 days both in community-dwelling patients (hazard ratio = 1.31; 95% confidence interval, 1.02 to 1.70) and in those living in long-term care facilities (hazard ratio = 1.55; 95% confidence interval, 1.15 to 2.07).\(^{33}\) Most of those deaths were related to cardiovascular or infectious causes, possibly because antipsychotics can prolong QT interval and cause sedation, which may increase the risk of aspiration. Other common adverse effects of antipsychotics include gait disturbances and extrapyramidal effects. Using atypical antipsychotics to treat behavioral symptoms such as agitation in patients with Alzheimer disease generally should be avoided because of adverse effects, although these agents may be appropriate in some situations.

Ineffective Therapies

Estrogen has been studied for the prevention and treatment of dementia. A Cochrane review found no beneficial effect of long-term estrogen use on cognitive function in patients with Alzheimer disease.\(^{34}\) Estrogen does not enhance the effects of acetylcholinesterase inhibitors; no benefit was found when it was used in combination with rivastigmine.\(^{35}\)

An updated Cochrane review concluded that there is no evidence supporting the use of vitamin E for the prevention or treatment of Alzheimer disease, and it may be harmful in higher doses.\(^{36}\) Studies have demonstrated no beneficial effect of nonsteroidal anti-inflammatory drugs for the treatment of Alzheimer disease.\(^{37-41}\) Statins and insulin sensitizers have not demonstrated benefit in clinical trials in patients with Alzheimer disease.\(^{42,43}\) Systematic reviews have found no clear benefit of lecithin or acetyl-L-carnitine.\(^{44,45}\)

Therapies with Conflicting Evidence

TESTOSTERONE

There is conflicting evidence on the benefit of testosterone in men with Alzheimer disease. Two randomized, double-blind, placebo-controlled studies demonstrated benefit in visuospatial cognition, but it is unclear if this effect is clinically meaningful.\(^{46,47}\) A randomized, placebo-controlled trial examined the effect of 1% testosterone gel supplementation (75 mg per day) in men with mild to moderate Alzheimer disease over a period of six months.\(^{48}\) No statistically significant benefits were detected, although testosterone treatment mildly improved patients’ quality of life. A randomized, double-blind, placebo-controlled trial of men older than 65 years with limited mobility and low testosterone levels evaluated treatment with testosterone gel or placebo. The results showed a significantly increased incidence of adverse cardiovascular effects in the treatment group over six months (22 versus 5 percent in the placebo group; \(P = .05\); number needed to harm = 6).\(^{49}\) Because of the risk of serious adverse effects and the paucity of clinically helpful effects, testosterone therapy in men with Alzheimer disease is not recommended.

GINKGO

A Cochrane Review evaluated 36 studies of ginkgo for the treatment of cognitive impairment and dementia.\(^{50}\) All but one study used the standard ginkgo extract EGB 761, at a dosage of 80 to 600 mg per day. Ginkgo was not associated with a consistent, clinically significant benefit in persons with Alzheimer disease. A European study of 96 patients with Alzheimer disease demonstrated equal effectiveness among a prescription ginkgo extract (240 mg per day), donepezil (5 to 10 mg per day), and a combination of the two agents.\(^{51}\) Because ginkgo is not available as a regulated prescription product in the United States, it is possible that the variability in dietary
supplement quality may account for the difference in findings. Clinical evidence appears to support the safety of ginkgo, with no additional adverse effects reported compared with placebo. However, possible drug-supplement interactions must be considered in patients with Alzheimer disease who use ginkgo, especially the risk of bleeding with the use of aspirin, nonsteroidal anti-inflammatory drugs, or anticoagulants. This is noteworthy because many patients with Alzheimer disease take aspirin for cardiovascular health.

**Approach to the Patient**

Guidelines on the treatment of Alzheimer disease are available from a number of organizations (*Table 3*), including one developed by the American Academy of Family Physicians, in conjunction with the

### Table 3. Summary of Guidelines for the Treatment of Alzheimer Disease

<table>
<thead>
<tr>
<th>Organization</th>
<th>Year of recommendation</th>
<th>Recommended therapy</th>
<th>Suggested monitoring</th>
<th>Recommendations on discontinuing therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Academy of Family Physicians and American College of Physicians&lt;sup&gt;15&lt;/sup&gt;</td>
<td>2008</td>
<td>Acetylcholinesterase inhibitors for mild to moderate disease</td>
<td>No recommendations</td>
<td>Discontinue with loss of effectiveness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Memantine (Namenda) for moderate to severe disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Geriatrics Society&lt;sup&gt;16&lt;/sup&gt;</td>
<td>2009</td>
<td>Acetylcholinesterase inhibitors for mild to moderate disease</td>
<td>MMSE, Clinical Dementia Rating, and Functional Assessment Staging scale</td>
<td>Discontinue if the patient develops severe impairment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Memantine plus donepezil (Aricept) for moderate to severe disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caregivers should commit to a trial treatment period of at least three months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Psychiatric Association&lt;sup&gt;2&lt;/sup&gt;</td>
<td>2007</td>
<td>Acetylcholinesterase inhibitors for mild to moderate disease</td>
<td>Every three to six months if patient is clinically stable; more frequently if adjusting medications</td>
<td>Discontinue with patient preference or loss of effectiveness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Memantine plus donepezil for moderate to severe disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>California Workgroup on Guidelines for Alzheimer’s Disease Management&lt;sup&gt;17&lt;/sup&gt;</td>
<td>2008</td>
<td>Acetylcholinesterase inhibitors for mild to moderate disease</td>
<td>After two to four weeks for adverse effects, then every six months to monitor effect on cognition and function</td>
<td>Discontinue before surgery or if there is continued deterioration at pretreatment rate after six months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Memantine plus an acetylcholinesterase inhibitor for moderate to severe disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canadian Consensus Conference on the Diagnosis and Treatment of Dementia&lt;sup&gt;18&lt;/sup&gt;</td>
<td>2007</td>
<td>Acetylcholinesterase inhibitors for mild to moderate disease</td>
<td>Regularly</td>
<td>Discontinue with patient preference, physician judgment, or severe disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Memantine plus an acetylcholinesterase inhibitor for moderate to severe disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Federation of Neurological Societies&lt;sup&gt;19&lt;/sup&gt;</td>
<td>2007</td>
<td>Acetylcholinesterase inhibitors for mild to moderate disease</td>
<td>Regular follow-up to assess cognitive function, activities of daily living, and behavioral symptoms</td>
<td>Discontinue if rapid worsening or an apparent loss of effectiveness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Memantine plus an acetylcholinesterase inhibitor for moderate to severe disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italian Association of Psychogeriatrics&lt;sup&gt;20&lt;/sup&gt;</td>
<td>2005</td>
<td>Acetylcholinesterase inhibitors for mild to severe disease</td>
<td>Cognitive function, activities of daily living, and behavioral and psychological symptoms</td>
<td>Discontinue if loss of effectiveness</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Memantine for moderate to severe disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Institute for Health and Clinical Excellence&lt;sup&gt;21&lt;/sup&gt;</td>
<td>2006</td>
<td>Acetylcholinesterase inhibitors for moderate disease</td>
<td>MMSE and global, functional, and behavioral assessment every six months</td>
<td>Discontinue with patient or caregiver preference, or physician judgment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MMSE = Mini-Mental State Examination.**

*Information from references 2, and 14 through 20.*
American College of Physicians. All guidelines emphasize the importance of educating patients and their families about the disease process and its expected course. Early referral to local support groups is recommended, and medicolegal issues such as driving and end-of-life planning should be addressed. Recommendations regarding pharmacologic treatment are described in Table 2, and a suggested algorithm for the treatment of Alzheimer disease is presented in Figure 1.

The decision to treat with medication should be shared with the patient and caregivers, including a discussion of the modest clinical benefit, adverse effects, and cost. Physicians should consider discontinuing therapy in patients who continue to decline despite maximal therapy. The National Institute on Aging and the Alzheimer’s Association have released recommendations on the diagnosis of dementia and mild cognitive impairment from Alzheimer disease; however, these guidelines do not address the treatment of Alzheimer disease and do not recommend the clinical use of biomarkers.

### Possible Future Treatments

Many potential therapeutic agents are currently under investigation for the treatment of Alzheimer disease. Amyloid precursor protein and enzymes involved in β-amyloid formation are thought to contribute to genetic forms of Alzheimer disease; therefore, interventions to reduce amyloid plaque burden by altering amyloid metabolism are being evaluated. Immunotherapy to promote clearance of β-amyloid from the central nervous system is being assessed. Advanced glycation end products are associated with aging. The advanced glycation end products receptor is a potential target to decrease plaque formation and inflammation. Other potential treatments include resveratrol, a compound from the skin of red grapes that may have beneficial effects on aging in mice, and latrepirdine, a N-methyl-D-aspartate receptor antagonist that may also weakly inhibit acetylcholinesterase, which may improve cognitive performance and is currently in phase 3 trials. Agents targeted against tau are other possible options.

---

### Treatment of Alzheimer Disease

**Figure 1. Algorithm for the treatment of Alzheimer disease.**

- Patient is diagnosed with Alzheimer disease
- Educate the patient and family about disease process
- Discuss medicolegal issues
- Provide information on support groups
- Refer to subspecialist if unable to perform appropriate follow-up, or if the patient or family requests a referral

**Patient’s condition is considered mild at diagnosis**
- Assess baseline functionality, medical and psychiatric state
- Minimize use of any anticholinergic medication
- Review medication options, including potential effectiveness, adverse effects, and cost

**Patient’s condition is considered moderate to severe at diagnosis**
- Begin treatment with acetylcholinesterase inhibitor
- Reevaluate patient two to four weeks after medication initiation; treat serious adverse effects

**Patient tolerates medication and is using stable dose**
- Follow up every three to six months, and continue treatment while patient’s condition is stable
- Change to another acetylcholinesterase inhibitor

**Patient is not tolerating medication, or his or her condition deteriorates based on functionality and caregiver’s input**
- Reevaluate patient two to four weeks after medication adjustment; treat serious adverse effects

**Patient’s condition deteriorates to moderate to severe Alzheimer disease**
- Add memantine

**Discontinue medications if:**
- Patient does not adhere to treatment
- Deterioration continues
- Patient develops serious comorbid disease or is terminally ill
- Patient or caregiver chooses to discontinue treatment
Alzheimer Disease

The Authors

BRADFORD T. WINSLOW, MD, FAAFP, is program director at the Swedish Family Medicine Residency, Littleton, Colo.

MARY K. ONYSKO, PharmD, BCPS, is assistant professor of pharmacy practice at the University of Wyoming School of Pharmacy, Laramie.

CHRISTIAN M. STOB, DO, is a staff physician at the Denver (Colo.) Health Medical Center.

KATHLEEN A. HAZLEWOOD, PharmD, BCPS, is assistant professor of pharmacy practice at the University of Wyoming School of Pharmacy.

Address correspondence to Bradford T. Winslow, MD, FAAFP, Swedish Family Medicine Residency, 191 E. Orchard Rd., Ste. 200, Littleton, CO 80121. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations to disclose.

REFERENCES


June 15, 2011 • Volume 83, Number 12 www.aafp.org/afp

American Family Physician 1411


